Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana

• Egile Nagusiak: Kelsi Swope (Egilea), Josh Morton (Egilea), Gregory P. Pogue (Egilea), Leigh Burden (Egilea), Nicholas Partain (Egilea), Steve Hume (Egilea), John Shepherd (Egilea), Carrie A. Simpson (Egilea), Miles B. Brennan (Egilea), Thomas C. Furman (Egilea), Sheila Kingrey-Gebe (Egilea), Theresa Martinez (Egilea), Jim McDonough (Egilea), Michael H. Pauly (Egilea), Kevin J. Whaley (Egilea), Larry Zeitlin (Egilea), Barry Bratcher (Egilea), Hugh Haydon (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The ongoing SARS-CoV-2 coronavirus pandemic of 2020-2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on Nicotiana benthamiana produced mAb therapeutics with high batch-to-batch reproducibility and f...